![]() |
市場調查報告書
商品編碼
2032398
醫藥研發外包市場報告:按服務、劑型、應用、最終用戶和地區分類(2026-2034 年)Formulation Development Outsourcing Market Report by Service, Dosage Form, Application, End User, and Region 2026-2034 |
||||||
2025年,全球醫藥研發外包市場規模達269億美元。展望未來,IMARC Group預測,到2034年,該市場規模將達到430億美元,2026年至2034年的複合年成長率為5.19%。研發成本上升、對專業知識的需求增加、藥物研發週期縮短、監管日益複雜以及製藥業的成長是推動市場成長的主要因素。
研發成本增加
製藥公司面臨高昂的研發成本,因此紛紛將製劑開發外包,以降低成本並更有效地配置資源。例如,根據產業報告顯示,默克公司2023年營收達601億美元,研發投入高達305億美元,年增126%,研發投入佔其2023年總營收的50.8%。同樣,強生公司在2023年也實現了強勁的財務成長,成為製藥業營收領先的公司之一。這家製藥巨頭在研發支出方面排名第三,投入約151億美元,創下公司歷史新高。製藥業的擴張無疑地提升了製劑開發外包市場的獲利能力。
對專業知識的需求日益成長
隨著藥物製劑日益複雜,對專業知識和先進技術的需求也日益成長,但許多製藥公司缺乏足夠的內部資源。例如,產業報告指出,印度製藥公司在全球學名藥(包括生物相似藥)出口領域的影響力表明,其戰略重心正轉向進一步拓展國際市場,尤其是美國市場。在這方面,美國FDA關於製劑開發的指導方針是推動印度製藥公司實現這一目標的關鍵動力。該指導方針草案概述了監管要求和最佳實踐,尤其針對面向美國市場的藥物製劑開發。遵循這些指導方針不僅能確保合規性,還能提高藥物的品質和療效。印度製藥業的專家認為,該指導方針如同藍圖,使其能夠開發符合國際標準的高品質製劑,從而增強其在全球市場的信譽和競爭力。外包合作夥伴能夠提供開發先進製劑所需的技能和最尖端科技,從而提升藥物的品質和療效,這為製劑開發外包市場帶來了光明的前景。
加強監管合規
嚴格的監管要求需要全面合規的配方流程,而擁有監管專業知識的外包合作夥伴可以有效地管理此流程。例如,根據一份行業報告,根據聯邦衛生署的通知,印度製藥公司必須在2024年前達到新的生產標準,但由於債務負擔,中小企業正在申請延期。根據修訂後的M類藥品監管條例,製藥公司必須將藥品召回情況通知許可機構,並報告產品缺陷、劣化或生產缺陷。此前,並沒有關於藥品召回通知許可機構的規定。預計這將進一步促進市場成長。
The global formulation development outsourcing market size reached USD 26.9 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 43.0 Billion by 2034, exhibiting a growth rate (CAGR) of 5.19% during 2026-2034. The increasing research and development (R&D) costs, the rising need for specialized expertise, accelerated drug development timelines, growing regulatory complexities, and the growing pharmaceutical sector are some of the major factors propelling the growth of the market.
Rising Research and Development (R&D) Costs
Pharmaceutical companies face high costs in research and development (R&D), prompting them to outsource formulation development to reduce expenses and allocate resources more efficiently. For instance, according to industry reports, Merck & Co's revenues reached $60.1bn in FY 2023, with research and development (R&D) investments peaking at $30.5bn. Displaying a staggering 126% growth over the course of one year, the company's research and development (R&D) investments now represent 50.8% of its total revenue for 2023. Similarly, in 2023 Johnson & Johnson (J&J) displayed strong financial growth and was the leading pharmaceutical company in terms of revenues. The pharma giant ranked third in terms of R&D expenditure, investing approximately $15.1bna record-breaking figure for the company. The pharmaceutical industry's expansion is positively enhancing the formulation development outsourcing market revenue.
Increasing Need for Specialized Expertise
The growing complexity of drug formulations requires specialized expertise and advanced technologies, which many pharmaceutical companies may lack internally. For instance, according to industry reports, Indian pharma's global presence in generic medicine exports among others like biosimilars will indicate a strategic shift toward further expansion in the international markets, particularly the US. To this end, the guidance from the US FDA on formulation development serves as a crucial enabler for Indian pharma companies in this pursuit. The draft guidance on formulation development outlines the regulatory requirements and best practices for developing drug formulations, especially those intended for the US market. Adhering to these guidelines not only ensures compliance but also enhances the quality and efficacy of pharmaceutical products. According to Indian pharma industry experts, for Indian pharmaceutical firms eyeing global expansion, such guidance provides a roadmap for developing high-quality formulations that meet international standards, thereby bolstering their credibility and competitiveness in the global arena. Outsourcing partners offer the necessary skills and cutting-edge technologies to develop sophisticated drug formulations that enhance the quality and efficacy of pharmaceutical products, thereby creating a positive formulation development outsourcing market outlook.
Growing Regulatory Compliance
Stringent regulatory requirements necessitate comprehensive and compliant formulation processes, which outsourcing partners with regulatory expertise can effectively manage. For instance, according to industry reports, Indian pharmaceutical companies must meet new manufacturing standards in 2024, as per a Union Health Ministry notification, although small companies have asked for a delay, citing their debt load. Under the revised Schedule M guidelines, pharmaceutical companies will have to inform the licensing authority about recalling a drug and report product defects, deterioration, or faulty production. Till now there was no provision for informing the licensing authority about drug recall. This is further expected to facilitate the market growth.
The publisher provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on service, dosage form, application, and end user.
Formulation Optimization accounts for the majority of the market share
The demand for formulation optimization in the market is driven by the need for enhanced drug efficacy, stability, and bioavailability. Increasing regulatory scrutiny necessitates robust and compliant formulations. Additionally, the rise of complex and personalized medicines requires precise formulation techniques. Outsourcing provides access to specialized expertise and advanced technologies, enabling efficient optimization. Moreover, the pressure to accelerate time-to-market and reduce development costs further fuels the demand for optimized formulations in the pharmaceutical industry. For instance, in July 2024, Pfizer announced that it had selected its preferred once-daily modified-release formulation for danuglipron, an oral glucagon-like peptide-1 (GLP-1) receptor agonist. Looking ahead, Pfizer plans to conduct dose optimization studies in the second half of 2024, evaluating multiple doses of the preferred modified release formulation to inform the registration enabling studies.
Injectable holds the largest share of the industry
The demand for injectable dosage forms in the market is driven by the growing prevalence of chronic diseases and the need for targeted and controlled drug delivery. Injectable forms offer rapid absorption and bioavailability, essential for critical care and biologic drugs. Additionally, the rise in biologics and biosimilars, which are predominantly administered via injection, fuels this demand. Outsourcing provides access to specialized manufacturing capabilities and regulatory expertise, ensuring high-quality and compliant injectable formulations. This, in turn, is enhancing the overall formulation development outsourcing market value.
Oncology represents the leading market segment
The demand for formulation development outsourcing in oncology is driven by the complexity of cancer treatments and the need for specialized expertise. Advancements in targeted therapies and personalized medicine require innovative formulation techniques. High research and development (R&D) costs and stringent regulatory requirements also necessitate outsourcing to manage these challenges efficiently which is driving the formulation development outsourcing demand. Additionally, the urgency to accelerate time-to-market for new cancer drugs pushes pharmaceutical companies to seek external partners with advanced technologies and experience in oncology formulation development.
Pharmaceutical and biopharmaceutical companies exhibits a clear dominance in the market
The demand for formulation development outsourcing in pharmaceutical and biopharmaceutical companies is driven by high research and development (R&D) costs, the need for specialized expertise, and advanced technologies. Outsourcing helps accelerate drug development timelines and ensures regulatory compliance. The complexity of new drug formulations, including biologics and personalized medicines, necessitates external expertise which is further influencing formulation development outsourcing market growth positively. Additionally, outsourcing allows companies to focus on core competencies while leveraging innovative solutions from specialized partners to enhance drug efficacy, stability, and market readiness.
North America leads the market, accounting for the largest formulation development outsourcing market share
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for formulation development outsourcing.
The high research and development (R&D) costs and the need for specialized expertise to develop complex drug formulations are driving the market growth in the region. The region's stringent regulatory environment necessitates compliance with rigorous standards, which outsourcing partners can manage efficiently. Additionally, the rise of biotechnology and personalized medicine requires advanced formulation solutions, further boosting the demand for outsourcing. According to the formulation development outsourcing market forecast across the region, the pressure to accelerate drug development timelines and reduce time-to-market also contributes to the growth of this market. For instance, in May 2024, Coriolis Pharma, a globally operating service provider for R&D and GMP drug product development, R&D and GMP analytics, and sterile drug product manufacturing support, announced the launch of a U.S. entity that allows customers to combine the convenience of a local service with the advantages of international expertise. U.S. customers will be served by the U.S.-based Coriolis commercial organization, which consists of business development and client project management professionals.